DGIdb - SLCO1B1 Gene Record

SLCO1B1 10599 Druggable Genome

Alternate Names:

10599
SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY MEMBER 1B1
SLCO1B1
HBLRR
LST-1
LST1
OATP-C
OATP1B1
OATP2
OATPC
SLC21A6
604843
10959
ENSG00000134538
OTTHUMG00000169047
1220
Q9Y6L6
PA134865839
SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B1 (SOLUTE CARRIER FAMILY 21, MEMBER 6) (SODIUM-INDEPENDENT ORGANIC ANION TRANSPORTING POLYPEPTIDE 2) (OATP 2) (LIVER-SPECIFIC ORGANIC ANION TRANSPORTER 1) (LST-1) (OATP-C). [SOURCE:UNIPROT/SWISSPRO
8450

Gene Info:

GuideToPharmacology Gene Category Name	SLCO family of organic anion transporting polypeptides
GuideToPharmacology Gene Category ID	238
Human Readable Name	DRUGGABLE GENOME
Gene Biotype	PROTEIN_CODING

(7 More Sources)

Gene Categories: Category Details

TRANSPORTER
DRUGGABLE GENOME

Publications:

Mei Y et al., 2015, Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients., J Clin Pharmacol
Varenhorst C et al., 2015, Effect of genetic variations on ticagrelor plasma levels and clinical outcomes., Eur Heart J
Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
Katz DA et al., 2006, Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics., Clin Pharmacol Ther
Kwara A et al., 2014, Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance., Pharmacotherapy
Li LM et al., 2012, SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury., Mol Med Rep
Chigutsa E et al., 2011, The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications., Antimicrob Agents Chemother
He YJ et al., 2009, Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism., Clin Chim Acta
Vavricka et al., 2002, Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver., Hepatology
Varma MV et al., 2015, Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide., Drug Metab Dispos
Sharma P et al., 2010, Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions., Xenobiotica
Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
Kalliokoski A et al., 2008, Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide., J Clin Pharmacol
Kameyama Y et al., 2005, Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells., Pharmacogenet Genomics
Iacobucci I et al., 2013, Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin., Pharmacogenomics J
Treiber et al., 2007, Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil., Drug Metab. Dispos.
Oh ES et al., 2013, Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans., Drug Metab Pharmacokinet
Wen J et al., 2010, OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers., J Clin Pharm Ther
Hirano M et al., 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans., J Pharmacol Exp Ther
Hirano M et al., 2006, Drug-drug interaction between pitavastatin and various drugs via OATP1B1., Drug Metab Dispos
Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
Dawed AY et al., 2016, CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes., Diabetes Care
Köck K et al., 2013, Interaction of silymarin flavonolignans with organic anion-transporting polypeptides., Drug Metab Dispos
Liu L et al., 2006, Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers., J Pharmacol Exp Ther
Nozawa et al., 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity., Drug Metab. Dispos.
Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
Smith et al., 2005, Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel., Cancer Biol. Ther.
Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood
Eldem İ et al., 2018, SLCO1B1 Polymorphisms are Associated With Drug Intolerance in Childhood Leukemia Maintenance Therapy., J Pediatr Hematol Oncol
Liu SG et al., 2017, Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia., Oncotarget
Moriyama T et al., 2015, Inherited genetic variation in childhood acute lymphoblastic leukemia., Blood
Goričar K et al., 2014, Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma., Pharmacogenet Genomics
Csordas K et al., 2014, Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia., Br J Haematol
Ramsey LB et al., 2013, Genome-wide study of methotrexate clearance replicates SLCO1B1., Blood
Mikkelsen TS et al., 2011, PharmGKB summary: methotrexate pathway., Pharmacogenet Genomics
Treviño LR et al., 2009, Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects., J Clin Oncol
Tirona RG et al., 2001, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans., J Biol Chem
Sandhu P et al., 2005, Hepatic uptake of the novel antifungal agent caspofungin., Drug Metab Dispos
Igel et al., 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin., Clin. Pharmacol. Ther.
Marcath LA et al., 2019, Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure., Pharmacogenomics
Kobie J et al., 2019, Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies., J Clin Pharmacol
Suwannakul S et al., 2008, Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism., J Hum Genet
Takeuchi K et al., 2011, Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent., Drug Metab Dispos
Oballa RM et al., 2011, Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia., J Med Chem
Maeda K et al., 2006, Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril., Clin Pharmacol Ther
Dragović G et al., 2020, Influence of SLCO1B1 polymorphisms on lopinavir C<sub>trough</sub> in Serbian HIV/AIDS patients., Br J Clin Pharmacol
Bins S et al., 2016, Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity., Pharmacogenomics
Tornio A et al., 2015, SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid., Pharmacogenet Genomics
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Hsiang B et al., 1999, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters., J Biol Chem
Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
Lau et al., 2007, effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers., Clin. Pharmacol. Ther.

CASPOFUNGIN SLCO1B1

Interaction Score: 2.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15716364

Sources:
PharmGKB
PITAVASTATIN SLCO1B1

Interaction Score: 1.5

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23007012 20175818 15159445 16595711

Sources:
PharmGKB
VALSARTAN SLCO1B1

Interaction Score: 1.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16678545

Sources:
PharmGKB
OLMESARTAN SLCO1B1

Interaction Score: 1.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18641915

Sources:
PharmGKB
LETERMOVIR SLCO1B1

Interaction Score: 1.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31022310

Sources:
PharmGKB
ELAGOLIX SLCO1B1

Interaction Score: 1.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
SILYBIN B SLCO1B1

Interaction Score: 1.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23401473

Sources:
DTC
MK-8245 SLCO1B1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21661758

Sources:
DTC
ISOSILYBIN A SLCO1B1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23401473

Sources:
DTC
ISOSILYBIN B SLCO1B1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23401473

Sources:
DTC
SILYDIANIN SLCO1B1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23401473

Sources:
DTC
ATRASENTAN SLCO1B1

Interaction Score: 0.8

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16513443

Sources:
PharmGKB
BOSENTAN SLCO1B1

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17496208

Sources:
PharmGKB
CERIVASTATIN SLCO1B1

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15970799

Sources:
PharmGKB
GEMFIBROZIL SLCO1B1

Interaction Score: 0.5

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
16316932 25941268 19919292

Sources:
NCI GuideToPharmacology
RIFAMPIN SLCO1B1

Interaction Score: 0.4

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of atorvastatin transport by OATP1B1.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
24420746 22562052 21709081 19374892 12085361

Sources:
GuideToPharmacology PharmGKB
ROCURONIUM SLCO1B1

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25279974

Sources:
PharmGKB
ELTROMBOPAG SLCO1B1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21422191

Sources:
DTC
SULFOBROMOPHTHALEIN SLCO1B1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21422191

Sources:
DTC
GLYCYRRHIZIN SLCO1B1

Interaction Score: 0.3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
AMPRENAVIR SLCO1B1

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
TICAGRELOR SLCO1B1

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25935875

Sources:
PharmGKB
LOPINAVIR SLCO1B1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32022294

Sources:
PharmGKB
NATEGLINIDE SLCO1B1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18187595

Sources:
PharmGKB
SILIBININ SLCO1B1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23401473

Sources:
DTC
CLOFIBRATE SLCO1B1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16316932

Sources:
NCI
LOVASTATIN SLCO1B1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26020121 16103896 10601278 15616150

Sources:
PharmGKB
TROGLITAZONE SLCO1B1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977862

Sources:
NCI PharmGKB
METHOTREXATE SLCO1B1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23652803 29683944 28525903 25999454 25098908 24712521 23233662 21317831 19901119 11477075

Sources:
CIViC PharmGKB
SIMEPREVIR SLCO1B1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATAZANAVIR SLCO1B1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FENOFIBRATE SLCO1B1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16316932

Sources:
NCI PharmGKB
FLUDARABINE SLCO1B1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
ENALAPRIL SLCO1B1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16627748

Sources:
PharmGKB
PRAVASTATIN SLCO1B1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Specific Action of the Ligand Binding

Endogenous Drug? False

Direct Interaction? False

PMIDs:
16678544

Sources:
NCI GuideToPharmacology
ROSIGLITAZONE SLCO1B1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27271184

Sources:
PharmGKB
ROSUVASTATIN SLCO1B1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
7-ETHYL-10-HYDROXYCAMPTOTHECIN SLCO1B1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18221820

Sources:
PharmGKB
CYTARABINE SLCO1B1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398 22584460

Sources:
PharmGKB
EPIRUBICIN SLCO1B1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB
MERCAPTOPURINE SLCO1B1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29683944

Sources:
PharmGKB
IDARUBICIN SLCO1B1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22584460

Sources:
PharmGKB
DOCETAXEL SLCO1B1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16210916 27234217

Sources:
NCI PharmGKB
MITOXANTRONE SLCO1B1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398

Sources:
PharmGKB
ETOPOSIDE SLCO1B1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398

Sources:
PharmGKB
ATORVASTATIN SLCO1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17192770

Sources:
NCI
RUCAPARIB SLCO1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAUNORUBICIN SLCO1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398

Sources:
PharmGKB
CYCLOPHOSPHAMIDE SLCO1B1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB
SORAFENIB SLCO1B1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27533851

Sources:
PharmGKB
DOXORUBICIN SLCO1B1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB
PACLITAXEL SLCO1B1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30520341

Sources:
PharmGKB
FLUOROURACIL SLCO1B1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB

Ensembl: ENSG00000134538
- Version: 101_38
Alternate Names:

SLCO1B1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

RussLampel: ENSG00000134538

Version: 26-July-2011

Alternate Names:

ENSG00000134538 Ensembl Gene Id

SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B1 (SOLUTE CARRIER FAMILY 21, MEMBER 6) (SODIUM-INDEPENDENT ORGANIC ANION TRANSPORTING POLYPEPTIDE 2) (OATP 2) (LIVER-SPECIFIC ORGANIC ANION TRANSPORTER 1) (LST-1) (OATP-C). [SOURCE:UNIPROT/SWISSPRO Description

SLCO1B1 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

GuideToPharmacology: 10599
- Version: 29-September-2020
Alternate Names:

10959 HUGO Gene ID

10959 HUGO Gene Symbol

solute carrier organic anion transporter family member 1B1 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name SLCO family of organic anion transporting polypeptides

GuideToPharmacology Gene Category ID 238

Gene Categories:

TRANSPORTER

Publications:

PharmGKB: SLCO1B1

Version: 18-August-2020

Alternate Names:

PA134865839 PharmGKB ID

Gene Info:

Publications:

Varenhorst C et al., 2015, Effect of genetic variations on ticagrelor plasma levels and clinical outcomes., Eur Heart J

Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther

Hirano M et al., 2004, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans., J Pharmacol Exp Ther

CIViC: SLCO1B1
- Version: 14-September-2020
Alternate Names:

10599 Entrez Gene ID

8450 CIViC Gene ID

Gene Info:

Publications:

Radtke et al., 2013, Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia., Blood

NCI: SLCO1B1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica

Igel et al., 2006, Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin., Clin. Pharmacol. Ther.

Nozawa et al., 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity., Drug Metab. Dispos.

DTC: SLCO1B1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Köck K et al., 2013, Interaction of silymarin flavonolignans with organic anion-transporting polypeptides., Drug Metab Dispos

Takeuchi K et al., 2011, Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent., Drug Metab Dispos

Oballa RM et al., 2011, Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia., J Med Chem

HingoraniCasas: ENSG00000134538
- Version: 31-May-2017
Alternate Names:

ENSG00000134538 Gene Symbol

SLCO1B1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
HumanProteinAtlas: SLCO1B1
- Version: 19.3
Alternate Names:

ENSG00000134538 Ensembl Gene ID

LST-1 Human Protein Atlas Gene Synonym

OATP-C Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

TRANSPORTER

Publications:
Pharos: SLCO1B1
- Version: 01-May-2021
Alternate Names:

Solute carrier organic anion transporter family member 1B1 Gene Name

Q9Y6L6 UniProt ID

Gene Info:

Gene Categories:

TRANSPORTER

Publications:
FDA: SLCO1B1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Details of the Assay for Interaction	Inhibition of atorvastatin transport by OATP1B1.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

Specific Action of the Ligand	Binding
Endogenous Drug?	False
Direct Interaction?	False

ENSG00000134538	Ensembl Gene Id
SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B1 (SOLUTE CARRIER FAMILY 21, MEMBER 6) (SODIUM-INDEPENDENT ORGANIC ANION TRANSPORTING POLYPEPTIDE 2) (OATP 2) (LIVER-SPECIFIC ORGANIC ANION TRANSPORTER 1) (LST-1) (OATP-C). [SOURCE:UNIPROT/SWISSPRO	Description
SLCO1B1	Display Id

10959	HUGO Gene ID
10959	HUGO Gene Symbol
solute carrier organic anion transporter family member 1B1	HUGO Gene Name

Solute carrier organic anion transporter family member 1B1	Gene Name
Q9Y6L6	UniProt ID

SLCO1B1 Gene Record

SLCO1B1 10599 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15716364

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23007012 20175818 15159445 16595711

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16678545

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18641915

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31022310

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23401473

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21661758

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23401473

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23401473

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23401473

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16513443

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17496208

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15970799

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

PMIDs: 16316932 25941268 19919292

Sources: NCI GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction Inhibition of atorvastatin transport by OATP1B1. Specific Action of the Ligand Inhibition Endogenous Drug? False

PMIDs: 24420746 22562052 21709081 19374892 12085361

Sources: GuideToPharmacology PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25279974

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21422191

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
15716364

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23007012 20175818 15159445 16595711

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16678545

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18641915

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31022310

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
23401473

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21661758

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23401473

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23401473

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23401473

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16513443

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17496208

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15970799

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
16316932 25941268 19919292

Sources:
NCI GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of atorvastatin transport by OATP1B1.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
24420746 22562052 21709081 19374892 12085361

Sources:
GuideToPharmacology PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25279974

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21422191

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21422191

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25935875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
32022294

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18187595

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23401473

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16316932